Cardioverter-Defibrillators (CPB 0585, reviewed 2026-04-22)
Aetna's Cardioverter-Defibrillators policy (CPB 0585, last review 04/22/2026) covers FDA-approved implantable cardioverter-defibrillators for members with listed indications, including spontaneously occurring ventricular fibrillation or sustained ventricular tachycardia not associated with acute myocardial infarction, and ischemic or non-ischemic dilated cardiomyopathy with NYHA class II or III heart failure and an LVEF of 35% or less on optimal medical therapy. Extravascular and subcutaneous defibrillators and wearable or non-wearable cardioverter-defibrillators are covered only under the criteria stated, while ICDs with hemodynamic monitoring, use in persons with left ventricular assist devices, and N-terminal pro-B type natriuretic peptide testing for prognosis of ICD implantation are listed as experimental, investigational or unproven.